Cytomed Therapeutics(GDTC.US)

Last Updated 19:00:00 ET
longbridge loading

CytoMed Chairman Moves to Boost Personal Stake Through Private Share Purchases

Tip Ranks·
US
GDTC
+9.09%
Tip Ranks·
US
GDTC
+9.09%

Anixa Biosciences Advances Breast Cancer Vaccine Toward Phase 2 After Positive Phase 1 Results; Cytovance Selected for cGMP Manufacturing | ANIX Stock News

StockTitan·
US
XBI
+3.88%
US
BIB
+4.98%
US
PBE
+1.60%
StockTitan·
US
XBI
+3.88%
US
BIB
+4.98%
US
PBE
+1.60%

Amplia Therapeutics Announces Opening of US Sites for Amplicity Pancreatic Cancer Trial | INNMF Stock News

StockTitan·
StockTitan·

12 Health Care Stocks Moving In Thursday's Pre-Market Session

benzinga_article·
US
ATPC
-3.24%
US
XBI
+3.88%
US
OMCL
+2.05%
benzinga_article·
US
ATPC
-3.24%
US
XBI
+3.88%
US
OMCL
+2.05%

Why Align Technology Shares Are Trading Higher By Over 10%; Here Are 20 Stocks Moving Premarket

benzinga_article·
US
XHE
+2.17%
US
CISS
+2.33%
US
BBH
+0.96%
benzinga_article·
US
XHE
+2.17%
US
CISS
+2.33%
US
BBH
+0.96%

12 Health Care Stocks Moving In Wednesday's Pre-Market Session

benzinga_article·
US
IHE
+0.84%
US
ONCY
+5.81%
US
IXJ
+0.35%
benzinga_article·
US
IHE
+0.84%
US
ONCY
+5.81%
US
IXJ
+0.35%

CytoMed Therapeutics Refutes Misleading Claims and Reaffirms Clinical Progress | GDTC Stock News

StockTitan·
US
BBH
+0.96%
US
SBIO
+3.75%
US
GDTC
+9.09%
StockTitan·
US
BBH
+0.96%
US
SBIO
+3.75%
US
GDTC
+9.09%

CytoMed Therapeutics (NASDAQ: GDTC) denies false claims, reaffirms progress in cancer treatment research in Singapore.

Unusual Whales·
US
GDTC
+9.09%
Unusual Whales·
US
GDTC
+9.09%
© 2026 Longbridge｜Disclaimer